within Pharmacolibrary.Drugs.ATC.C;

model C02KX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00028333333333333335,
    adminDuration  = 600,
    adminMass      = 125 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005166666666666667,
    Tlag           = 12.0,            
    Vdp             = 0.009,
    k12             = 19,
    k21             = 19
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bosentan is a dual endothelin receptor antagonist used primarily in the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and decrease the rate of clinical worsening. It is an orally active drug that is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Chin, K, &amp; Channick, R (2004). Bosentan. <i>Expert review of cardiovascular therapy</i> 2(2) 175–182. DOI:<a href=\"https://doi.org/10.1586/14779072.2.2.175\">10.1586/14779072.2.2.175</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15151466/\">https://pubmed.ncbi.nlm.nih.gov/15151466</a></p></li><li><p>Puza, N, et al., &amp; DeClue, A (2014). Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats. <i>Journal of veterinary pharmacology and therapeutics</i> 37(2) 192–195. DOI:<a href=\"https://doi.org/10.1111/jvp.12083\">10.1111/jvp.12083</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24745065/\">https://pubmed.ncbi.nlm.nih.gov/24745065</a></p></li><li><p>Zhang, W, et al., &amp; Zhao, W (2020). Oral drugs used to treat persistent pulmonary hypertension of the newborn. <i>Expert review of clinical pharmacology</i> 13(12) 1295–1308. DOI:<a href=\"https://doi.org/10.1080/17512433.2020.1850257\">10.1080/17512433.2020.1850257</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33180564/\">https://pubmed.ncbi.nlm.nih.gov/33180564</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KX01;
